A Peptide Antagonist of the TLR4-MD2 Interaction

Overview

Journal Chembiochem

Specialty Biochemistry

Date 2009 Feb 3

PMID 19184989

Citations 26

Authors

Peter F Slivka

Mitesh Shridhar

Gui-in Lee

Deanne W Sammond

Mark R Hutchinson

Alexander J Martinko

Madison M Buchanan

Page W Sholar

Jeffrey J Kearney

Jacqueline A Harrison

Linda R Watkins

Hang Yin

Affiliations

Soon will be listed here.

Abstract

Toll-like receptors are an integral part of innate immunity in the central nervous system (CNS); they orchestrate a robust defense in response to both exogenous and endogenous danger signals. Recently, toll-like receptor 4 (TLR4) has emerged as a therapeutic target for the treatment of CNS-related diseases such as sepsis and chronic pain. We herein report a chemical biology approach by using a rationally designed peptide inhibitor to disrupt the TLR4-MD2 association, thereby blocking TLR4 signaling.

Citing Articles

By-Product Extracts from Counteract Hallmarks of Neuroinflammation in a Microglial Model.

Marrazzo P, Mandrone M, Chiocchio I, Zambonin L, Barbalace M, Zalambani C Antioxidants (Basel). 2023; 12(4).

PMID: 37107183 PMC: 10135167. DOI: 10.3390/antiox12040808.

Antimicrobial peptides could antagonize uncontrolled inflammation Toll-like 4 receptor.

Buccini D, Roriz B, Rodrigues J, Franco O Front Bioeng Biotechnol. 2022; 10:1037147.

PMID: 36568291 PMC: 9767961. DOI: 10.3389/fbioe.2022.1037147.

HSP60-Derived Peptide as an LPS/TLR4 Modulator: An Approach.

Vila-Casahonda R, Lozano-Aponte J, Guerrero-Beltran C Front Cardiovasc Med. 2022; 9:731376.

PMID: 35433873 PMC: 9010565. DOI: 10.3389/fcvm.2022.731376.

Molecular mechanism underlying the TLR4 antagonistic and antiseptic activities of papiliocin, an insect innate immune response molecule.

Krishnan M, Choi J, Jang A, Choi S, Yeon J, Jang M Proc Natl Acad Sci U S A. 2022; 119(10):e2115669119.

PMID: 35238667 PMC: 8915966. DOI: 10.1073/pnas.2115669119.

Large-scale survey and database of high affinity ligands for peptide recognition modules.

Teyra J, Kelil A, Jain S, Helmy M, Jajodia R, Hooda Y Mol Syst Biol. 2021; 16(12):e9310.

PMID: 33438817 PMC: 7724964. DOI: 10.15252/msb.20199310.

References

Visintin A, Latz E, Monks B, Espevik T, Golenbock D . Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem. 2003; 278(48):48313-20. DOI: 10.1074/jbc.M306802200. View

Dunbrack Jr R, Cohen F . Bayesian statistical analysis of protein side-chain rotamer preferences. Protein Sci. 1997; 6(8):1661-81. PMC: 2143774. DOI: 10.1002/pro.5560060807. View

Bronstein I, Fortin J, Stanley P, Stewart G, Kricka L . Chemiluminescent and bioluminescent reporter gene assays. Anal Biochem. 1994; 219(2):169-81. DOI: 10.1006/abio.1994.1254. View

Bacsa B, Kappe C . Rapid solid-phase synthesis of a calmodulin-binding peptide using controlled microwave irradiation. Nat Protoc. 2007; 2(9):2222-7. DOI: 10.1038/nprot.2007.300. View

Cao H, Zhang Y . Spinal glial activation contributes to pathological pain states. Neurosci Biobehav Rev. 2008; 32(5):972-83. DOI: 10.1016/j.neubiorev.2008.03.009. View

Matzinger P . The danger model: a renewed sense of self. Science. 2002; 296(5566):301-5. DOI: 10.1126/science.1071059. View

Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K . MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999; 189(11):1777-82. PMC: 2193086. DOI: 10.1084/jem.189.11.1777. View

Guo L, Schluesener H . The innate immunity of the central nervous system in chronic pain: the role of Toll-like receptors. Cell Mol Life Sci. 2007; 64(9):1128-36. PMC: 11136004. DOI: 10.1007/s00018-007-6494-3. View

Dantas G, Corrent C, Reichow S, Havranek J, Eletr Z, Isern N . High-resolution structural and thermodynamic analysis of extreme stabilization of human procarboxypeptidase by computational protein design. J Mol Biol. 2007; 366(4):1209-21. PMC: 3764424. DOI: 10.1016/j.jmb.2006.11.080. View

10.

Schnabl B, Brandl K, Fink M, Gross P, Taura K, Gabele E . A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. Biochem Biophys Res Commun. 2008; 375(2):210-4. DOI: 10.1016/j.bbrc.2008.07.150. View

11.

DeLeo J, Tanga F, Tawfik V . Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist. 2004; 10(1):40-52. DOI: 10.1177/1073858403259950. View

12.

Tanga F, Raghavendra V, DeLeo J . Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem Int. 2004; 45(2-3):397-407. DOI: 10.1016/j.neuint.2003.06.002. View

13.

Kim H, Park B, Kim J, Kim S, Lee J, Oh S . Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007; 130(5):906-17. DOI: 10.1016/j.cell.2007.08.002. View

14.

Evans J, Falke J . Ca2+ influx is an essential component of the positive-feedback loop that maintains leading-edge structure and activity in macrophages. Proc Natl Acad Sci U S A. 2007; 104(41):16176-81. PMC: 2042181. DOI: 10.1073/pnas.0707719104. View

15.

Rohl C, Strauss C, Misura K, Baker D . Protein structure prediction using Rosetta. Methods Enzymol. 2004; 383:66-93. DOI: 10.1016/S0076-6879(04)83004-0. View

16.

Lehnardt S, Massillon L, Follett P, Jensen F, Ratan R, Rosenberg P . Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A. 2003; 100(14):8514-9. PMC: 166260. DOI: 10.1073/pnas.1432609100. View

17.

Nishitani C, Mitsuzawa H, Sano H, Shimizu T, Matsushima N, Kuroki Y . Toll-like receptor 4 region Glu24-Lys47 is a site for MD-2 binding: importance of CYS29 and CYS40. J Biol Chem. 2006; 281(50):38322-9. DOI: 10.1074/jbc.M606904200. View

18.

Akira S, Uematsu S, Takeuchi O . Pathogen recognition and innate immunity. Cell. 2006; 124(4):783-801. DOI: 10.1016/j.cell.2006.02.015. View

19.

Leon C, Tory R, Jia J, Sivak O, Wasan K . Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res. 2008; 25(8):1751-61. PMC: 2469272. DOI: 10.1007/s11095-008-9571-x. View

20.

Takeda K, Akira S . TLR signaling pathways. Semin Immunol. 2004; 16(1):3-9. DOI: 10.1016/j.smim.2003.10.003. View